Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134640 | 0.97 | MEN1 (0.67) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL3777713 | 0.88 | TDP1 (0.69) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL4060747 | 0.86 | TDP1 (0.67) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL136844 | 0.86 | TDP1 (0.74) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL4060445 | 0.85 | TDP1 (0.65) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL135846 | 0.84 | TDP1 (0.72) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL135520 | 0.84 | TDP1 (0.64) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL135664 | 0.84 | ALDH1A1 (0.73) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL3656064 | 0.84 | ALDH1A1 (0.81) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL135449 | 0.83 | TDP1 (0.71) | TDP1MAPTALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | GABBR1, CHRNA5, CHRNA3 | TDP1 965/4885MAPT 1326/4885ALDH1A1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.